![Sage Mandel](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Sage Mandel
Directeur/Membre du Conseil chez
CELYAD ONCOLOGY SA
Profil
Sage Mandel currently works at Celyad Oncology SA, as Non-Executive Director.
Ms. Mandel also formerly worked at Essex Woodlands Management, Inc., as Vice President from 2021 to 2023.
Ms. Mandel received her graduate degree in 2015 from the University of Pennsylvania.
Postes actifs de Sage Mandel
| Sociétés | Poste | Début |
|---|---|---|
| CELYAD ONCOLOGY SA | Directeur/Membre du Conseil | - |
Anciens postes connus de Sage Mandel
| Sociétés | Poste | Fin |
|---|---|---|
Essex Woodlands Management, Inc.
 Essex Woodlands Management, Inc. Investment ManagersFinance EW Healthcare Partners invests in public and private companies located in the North America, Latin America, Asia, and Europe with revenues ranges from USD 20 - 200 million. The firm focuses on sectors such as pharmaceutical, medical device, healthcare services, and healthcare IT. The firm participates in growth capital requirements with an investment size range from USD 20 - 100 million. It takes minority or majority interest and requires a board position. | Analyste en capital-investissement | 31/12/2020 |
Formation de Sage Mandel
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
94
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Essex Woodlands Management, Inc.
Essex Woodlands Management, Inc. Investment ManagersFinance EW Healthcare Partners invests in public and private companies located in the North America, Latin America, Asia, and Europe with revenues ranges from USD 20 - 200 million. The firm focuses on sectors such as pharmaceutical, medical device, healthcare services, and healthcare IT. The firm participates in growth capital requirements with an investment size range from USD 20 - 100 million. It takes minority or majority interest and requires a board position. | Finance |
Celyad Oncology SA
 Celyad Oncology SA BiotechnologyHealth Technology Develops immuno-oncology and cardiology products | Health Technology |
Choisissez Zonebourse 
